Breast Cancer

We will be reporting directly from the annual congress of the European Society for Medical Oncology (ESMO) in Munich, Germany, from October 19 to October 23.

The MONALEESA-7 trial shows that therapy with a CDK4/6 inhibitor, ribociclib, improves overall survival in combination with endocrine therapy. In addition, it demonstrates that CDK4/6 inhibition is equally effective in younger women.

We will be reporting directly from the annual congress of the European Society for Medical Oncology (ESMO) in Munich, Germany, from October 19 to October 23.